What Меларитм Treats: Main Uses and Benefits

Меларитм is applied across domains where additional symptomatic support is needed to address sleep disturbances and is considered relevant for supporting the body's sleep timing. Its application includes the short-term treatment of primary insomnia characterized by poor sleep quality.

This therapeutic domain is primarily focused on managing persistent symptoms related to difficulty staying asleep throughout the nocturnal period, and is relevant for easing the resulting feeling of unrefreshed rest. The medicine is also considered in the context of chronic sleep disturbances associated with functional imbalance, such as those that may occur with advancing age (specifically in patients aged 55 or over). This functional support may contribute to improved comfort during symptomatic periods.

The medication is utilized in situations involving certain distressing symptoms of the sleep-wake cycle, contributing to easing the overall symptom load of non-restorative rest.

The medicine may assist with maintaining a stable sleep pattern, providing supportive relief when symptoms interfere with routine activities and supporting general well-being.

Quick Fact: Relief for Poor Sleep Quality
Used for managing: Symptoms of persistent sleep maintenance difficulty and functional circadian rhythm disruption.
Main benefit: The medicine supports a stable, sustained sleep pattern and may assist with maintaining functional stability upon waking.

Regulatory References

1. European Medicines Agency Melatonin Neurim Overview

Who Can and Cannot Use Меларитм?

This section outlines the population eligibility rules for Меларитм (Melatonin Prolonged-Release) as documented in official government regulatory information.

---

Approved Age Group and Contraindications

Меларитм is officially indicated for adults aged 55 years and over for the short-term treatment of primary insomnia. Use is not recommended in children and adolescents under 18 years for this condition, as efficacy and safety have not been established in this general age group.

The medicine is formally contraindicated (must not be used) in patients with known hypersensitivity to melatonin or any of the inactive ingredients, and in individuals with rare hereditary problems such as galactose intolerance or Lapp lactase deficiency.

---

Restrictions Based on Health Status

Population Group	Regulatory Status
Hepatic Impairment	Use is not recommended due to potential for reduced drug clearance.
Autoimmune Diseases	Use is not recommended due to a lack of clinical data.
Severe Renal Impairment	Use is not recommended; caution is advised for any renal impairment.
Pregnancy and Lactation	Use is not recommended in pregnant or breastfeeding women.

The official labeling advises caution when using the medicine if you are driving or operating machinery, as drowsiness may occur.

Interactions with other medicines and products

Official regulatory information defines the interaction profile of this medicine based on its relationship with the P-glycoprotein (P-gp) efflux transporter. The drug is classified as a recognized substrate of P-gp, meaning its systemic exposure is subject to change when co-administered with other medicines that affect P-gp activity.

---

Documented Interaction Categories and Constraints

The primary mechanistic basis for clinically relevant interactions is the pharmacokinetic effect of co-administered agents on P-gp transport. These interactions fall into two distinct domains, each with specific regulatory constraints:

• P-gp Inhibitors: Co-administration with medicinal products classified as P-gp inhibitors results in an increased exposure of this medicine. This effect may require a reduction in the drug's dosage to maintain safe therapeutic levels, as officially defined in regulatory documentation.

• P-gp Inducers: Co-administration with medicinal products classified as P-gp inducers results in a decreased exposure of this medicine. Due to the risk of rendering the drug ineffective, official labeling may require avoidance of concurrent use with strong P-gp inducers.

These constraints establish the framework for managing the medicine's use with a wide range of other products, focusing strictly on alterations to the drug's exposure resulting from P-gp modulation.

Targeting the Central Circadian Clock

Меларитм is a full agonist at the Melatonin Receptor Type 1 ( MT1) and Type 2 ( MT2) receptors, which are primarily located on neurons within the Suprachiasmatic Nucleus ( SCN), the brain’s master clock. This mechanism involves activating a Gi protein signaling pathway that transmits the fundamental biological signal for nightfall. The action is defined as chronobiotic.

️ Modulation of Neuronal Signaling

Agonism at these receptors triggers an intracellular cascade that leads to the inhibition of adenylyl cyclase and the opening of specific potassium ion channels. This molecular sequence causes the SCN neurons to hyperpolarize—meaning their spontaneous firing rate is slowed down. The resulting physiological effect is a reduced transmission of wake-promoting signals from the SCN and a phase adjustment of the intrinsic core timing.

Sustained Phase Adjustment

The effect of this mechanism is the phase adjustment and synchronization of the overall sleep-wake cycle, supported by the concurrent lowering of core body temperature. The prolonged-release formulation provides the sustained receptor activation that resembles the natural nocturnal hormone profile.

How to Use Меларитм

Меларитм is administered via the oral route as a 2 mg prolonged-release tablet. The usage pattern is designed to deliver the active ingredient over a sustained period, simulating the natural release of melatonin during the night. The standard administration of the fixed 2 mg dose is based on established parameters regarding frequency and timing.

Administration Scope and Dosing Rules

The medicine is administered once daily according to set procedural conditions. Adherence to these conditions is essential to maintain the integrity of the specialized prolonged-release formulation.

Usage Entity	Official Administration Guidelines
Standard Dose	2 mg once daily
Frequency	Once daily (QD)
Timing & Food	Taken 1–2 hours before bedtime and after food
Duration	Intended for short-term treatment, typically up to 13 weeks

Procedural Constraints

Guidelines exist regarding the handling of the tablets. To prevent the rapid, uncontrolled release of the active ingredient, the prolonged-release tablets must be swallowed whole and must not be crushed, broken, or chewed. In cases where a dose is missed, it should be taken when remembered, provided it is before a certain point in the morning; otherwise, the missed dose is skipped, and the regular schedule is resumed the following evening.

Age-Specific Use: The standard 2 mg regimen is primarily defined for patients aged 55 years and older. Use is generally not recommended in the presence of severe hepatic impairment.

Research Evidence / Overview of Studies for Меларитм

Evidence for Use in Poor Sleep Quality and Insomnia

The core evidence base for this medicine comes from short-term, randomized, double-blind, placebo-controlled trials (RCTs). These are key clinical trials used in research exploring how symptoms change over time. Studies monitored how symptoms evolved in the observed populations, with researchers primarily focused on outcomes related to functional imbalance and daily functioning.

Research has explored whether the studied populations showed changes in patient-reported outcomes when compared to a non-active pill, such as the time taken to fall asleep (Sleep Onset Latency) and overall subjective sleep quality. These findings describe patterns observed in the studies over brief periods, typically three weeks, and help contextualize how patients reported their experience.

Research Focus on Older Adults (Aged 55 and Over)

The greatest volume of evidence is concentrated on patients aged 55 years and older. This research was conducted in populations with primary insomnia, a condition involving periods of heightened symptoms of poor sleep quality. Research examined outcomes reflecting daily functioning, such as self-assessed morning alertness and behavioral outcomes following wakening, which are relevant in trials assessing short-term or episodic symptom patterns. The studies report that certain patterns were observed in this population compared to younger groups.

Long-Term Observation and Sustained Effects

Studies exploring the data beyond the initial short-term period are available, primarily through open-label extensions of the main trials. These observational settings were designed to monitor data over defined time intervals, extending up to six months or, in some instances, a full year.

However, the certainty remains low when drawing conclusions from these open-label studies compared to the original double-blind RCTs. These studies lack blinding, which limits their ability to provide high-certainty evidence. The evidence contributes to the broader evidence landscape but provides limited certainty regarding the durability of observed patterns.

What Remains Uncertain in the Research Landscape

The current research landscape highlights several areas where more information is needed. Data are still emerging regarding the long-term observation of effects. The most robust evidence is largely confined to the older adult population (age 55 and over), and data for younger adults remain insufficient.

Furthermore, the data indicate patterns related to changes in symptoms largely reported through patient questionnaires and sleep diaries; the core studies did not rely on objective sleep data as the primary assessment. The magnitude of change measured in sleep parameters is noted in scientific literature as a recognized element of the research limitations. Comparative evidence is lacking regarding direct head-to-head trials against other sleep medications.

Key Studies & References

1. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety (Wade et al., 2010)

Common questions about Меларитм (FAQ)

---

Q: How quickly does Меларитм start to work?

The medicine is a prolonged-release tablet designed to maintain a concentration over several hours, intended to resemble the body's natural nocturnal melatonin profile. Regulatory information advises that the tablet should be taken 1 to 2 hours before the intended bedtime to allow the prolonged action to begin.

---

Q: Is Меларитм considered a sleeping pill?

Official classifications categorize the active ingredient in this medicine as a melatonin receptor agonist, which belongs to the broader pharmacotherapeutic group of hypnotics and sedatives. However, its specific function is not just to induce sedation but to modulate the body's sleep-wake cycle. The active ingredient works to help regulate the body's natural circadian rhythm.

---

Q: Does Меларитм interact with alcohol?

Yes, official regulatory documents caution against concurrent use of this medicine with alcohol. Alcohol can enhance the effect of the medicine, potentially leading to increased drowsiness or sedation.

---

Q: Can I take Меларитм with antianxiety medication?

Melatonin may enhance the sedative effect of certain medications, including benzodiazepines and non-benzodiazepine hypnotics, which are often used for anxiety or sleep. If taking this medicine alongside any anxiety medication, consultation with a healthcare professional is recommended.

---

Q: Are there any foods I should avoid while taking Меларитм?

The tablet is specifically instructed in official labeling to be taken after food. In some formulations, individuals with impaired glucose tolerance or diabetes may need to time the dose at least two to three hours after a meal. Refer to the official product instructions regarding meal timing for the most accurate guidance.

---

Q: Does Меларитм interact with common pain relievers like ibuprofen or aspirin?

Regulatory information advises informing a healthcare professional if you are taking common pain relievers, particularly nonsteroidal anti-inflammatory drugs (NSAIDs). These medications may interact and potentially alter the sedative effects of melatonin.

---

Q: Is it normal to feel a bit dizzy after taking Меларитм?

Dizziness is a documented adverse reaction to this medicine. According to official product information, dizziness is classified as uncommon, meaning it may affect up to 1 in 100 people. If dizziness or other unwanted effects occur, you should inform a healthcare provider.

---

Q: Why is Меларитм sometimes prescribed for jet lag?

The active ingredient in this medicine is known for its role in helping to regulate the body's circadian rhythm, which controls the sleep-wake cycle. While this specific prolonged-release formulation is primarily indicated for insomnia in older adults, other melatonin products are commonly approved for the short-term treatment of jet lag.

---

Q: Does Меларитм lose its effectiveness over time?

The medicine is indicated only for short-term treatment of insomnia, typically up to 13 weeks. This short treatment period is based on the evidence available. If sleep problems persist beyond this time, the treatment requires re-evaluation by a healthcare professional.

---

Q: Can Меларитм interfere with birth control pills?

Official labeling advises caution if you are receiving oestrogen therapy, such as in the form of oral contraceptives or hormone replacement therapy. Oestrogens can potentially increase the levels of melatonin in the body by slowing its metabolism. This is why caution is advised, and consultation with a healthcare professional is recommended.

---

Q: Is it possible to take too much Меларитм?

Yes, taking more than the prescribed amount is considered an overdose. Official documents state that an overdose may result in symptoms such as marked drowsiness, dizziness, headache, and confusion. If an overdose is suspected, immediate medical attention should be sought.

---

Q: Does Меларитм cause dry mouth?

Dry mouth is a documented side effect of this medication. It is classified as an uncommon adverse reaction, meaning it may affect up to 1 in 100 people who use the medicine. Always refer to the full safety information for a complete list of possible effects.

---

Q: Does Меларитм affect blood pressure?

Yes, changes in blood pressure have been documented as a possible side effect. Hypertension (high blood pressure) is classified in regulatory materials as an uncommon adverse reaction, affecting up to 1 in 100 users.

---

Q: Are there different strengths or dosages of Меларитм available?

The specific prolonged-release formulation of this drug is generally available in one fixed strength of 2 mg, as defined in regulatory documents. This single strength is used for the approved short-term treatment of insomnia in older adults.

---

Q: How long is Меларитм intended to be used?

This medicine is indicated for short-term treatment only. Regulatory documents specify that it is typically intended for use up to 13 weeks. Treatment beyond this period should be managed by a healthcare professional.

---

Q: Can Меларитм affect my driving ability?

Yes, official safety information states that the medicine has a moderate influence on the ability to drive or operate heavy machinery. This is because drowsiness, a known side effect, may occur and affect alertness.

How to Store and Dispose of Меларитм

Storage and disposal of Меларитм (melatonin prolonged-release tablets) must align with official regulatory requirements to ensure product stability and safety.

Mandatory Storage Conditions

The medicine must be stored below 25 C. It is mandatory to keep the tablets in the original container to provide protection from both light and moisture.

Stability and Child Safety

To ensure safety, the product must be stored out of the sight and reach of children. The medicine should not be used after the expiration date printed on the packaging.

Disposal Instructions

Disposal of unused or expired Меларитм must be conducted according to local requirements. Official guidelines prohibit disposing of the product via wastewater or household waste.